Trial · NCT02523690
Evaluating Muscle Weakness Improvement With Lorcaserin in ICU
NCT02523690, Phase 1, Phase 2, Terminated, Johns Hopkins University; results first posted 2020-01-13
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Evaluating Muscle Weakness Improvement With Lorcaserin in ICU. Trials, record NCT02523690. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02523690
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluating Muscle Weakness Improvement With Lorcaserin in ICU
- NCT number
- NCT02523690
- Status
- Terminated
- Phases
- Phase 1, Phase 2
- Enrollment
- 5 participants, actual
- Lead sponsor
- Johns Hopkins University
- Conditions
- Muscle Weakness, Sepsis
- Interventions
- Lorcaserin, Placebo
- First posted
- 2015-08-14
- Last updated
- 2020-01-13
- Results first posted
- 2020-01-13
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Handgrip Strength as Measured by Hand Dynamometer | Baseline and 2 to 6 hours after administration of 30mg lorcaserin/placebo | Hand grip strength measured using a dynamometer (measured in kilograms, then compared to age- and sex-matched population norms to yield percent predicted strength - higher is better) |
| Secondary | Change in Handgrip Strength as Measured by Hand Dynamometer | Baseline and 2 to 6 hours after administration of 10mg lorcaserin/placebo | Hand grip strength measured using a dynamometer (measured in kilograms, then compared to age- and sex-matched population norms to yield percent predicted strength - higher is better) |
| Secondary | Change in Manual Muscle Strength as Measured by the Medical Research Council (MRC) Score | Baseline and 2 to 6 hours after administration of 30mg lorcaserin/placebo | Measuring strength of 6 muscle groups in arms and legs using Medical Research Council composite score (each muscle group scored from scale of 0 \[no visible or noticeable contraction\] to 5 \[maximum strength\] and the sum of the scores for the 6 muscle groups equate to a composite score ranging from 0 to 60, higher score is better). |
| Secondary | Change in Manual Muscle Strength as Measured by the Medical Research Council (MRC) Score | Baseline and 2 to 6 hours after administration of 10mg lorcaserin/placebo | Measuring strength of 6 muscle groups in arms and legs using Medical Research Council composite score (each muscle group scored from scale of 0 \[no visible or noticeable contraction\] to 5 \[maximum strength\] and the sum of the scores for the 6 muscle groups equate to a composite score ranging from 0 to 60, higher score is better). |
| Secondary | Change in Quadriceps Strength as Measured by Handheld Dynamometer | Baseline and 2 to 6 hours after administration of 30mg lorcaserin/placebo | Strength (in kilograms) - measured via handheld dynamometry of quadriceps muscle. |
| Secondary | Change in Quadriceps Strength as Measured by Handheld Dynamometer | Baseline and 2 to 6 hours after administration of 10mg lorcaserin/placebo | Strength (in kilograms) - measured via handheld dynamometry of quadriceps muscle. |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Handgrip Strength as Measured by Hand Dynamometer | Baseline and 2 to 6 hours after administration of 30mg lorcaserin/placebo | percent of predicted strength | MEAN | |
| SECONDARY | Change in Handgrip Strength as Measured by Hand Dynamometer | Baseline and 2 to 6 hours after administration of 10mg lorcaserin/placebo | percent of predicted strength | MEAN | |
| SECONDARY | Change in Manual Muscle Strength as Measured by the Medical Research Council (MRC) Score | Baseline and 2 to 6 hours after administration of 30mg lorcaserin/placebo | score on a scale | MEAN | |
| SECONDARY | Change in Manual Muscle Strength as Measured by the Medical Research Council (MRC) Score | Baseline and 2 to 6 hours after administration of 10mg lorcaserin/placebo | score on a scale | MEAN | |
| SECONDARY | Change in Quadriceps Strength as Measured by Handheld Dynamometer | Baseline and 2 to 6 hours after administration of 30mg lorcaserin/placebo | kilograms | MEAN | |
| SECONDARY | Change in Quadriceps Strength as Measured by Handheld Dynamometer | Baseline and 2 to 6 hours after administration of 10mg lorcaserin/placebo | kilograms | MEAN |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Handgrip Strength as Measured by Hand Dynamometer | Intervention | 0.67 | Standard Deviation 2.93 | percent of predicted strength | |
| Change in Handgrip Strength as Measured by Hand Dynamometer | Control | 1.75 | Standard Deviation 1.06 | percent of predicted strength | |
| Change in Handgrip Strength as Measured by Hand Dynamometer | Intervention | -3.83 | Standard Deviation 1.89 | percent of predicted strength | |
| Change in Handgrip Strength as Measured by Hand Dynamometer | Control | 2.25 | Standard Deviation 0.35 | percent of predicted strength | |
| Change in Manual Muscle Strength as Measured by the Medical Research Council (MRC) Score | Intervention | 0.33 | Standard Deviation 3.5 | score on a scale | |
| Change in Manual Muscle Strength as Measured by the Medical Research Council (MRC) Score | Control | 3.50 | Standard Deviation 2.12 | score on a scale | |
| Change in Manual Muscle Strength as Measured by the Medical Research Council (MRC) Score | Intervention | 1.00 | Standard Deviation 1.73 | score on a scale | |
| Change in Manual Muscle Strength as Measured by the Medical Research Council (MRC) Score | Control | 0.50 | Standard Deviation 0.71 | score on a scale | |
| Change in Quadriceps Strength as Measured by Handheld Dynamometer | Intervention | -0.23 | Standard Deviation 1.83 | kilograms | |
| Change in Quadriceps Strength as Measured by Handheld Dynamometer | Control | 4.15 | Standard Deviation 2.19 | kilograms |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Intervention | 3 | |
| Overall Study | STARTED | Control | 2 | |
| Overall Study | COMPLETED | Intervention | 3 | |
| Overall Study | COMPLETED | Control | 2 | |
| Overall Study | NOT COMPLETED | Intervention | 0 | |
| Overall Study | NOT COMPLETED | Control | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Intervention | 0 | 3 |
| Total, all-cause mortality | Control | 0 | 2 |
| Total, other adverse events | Intervention | 0 | 3 |
| Total, other adverse events | Control | 0 | 2 |
| Total, serious adverse events | Intervention | 0 | 3 |
| Total, serious adverse events | Control | 0 | 2 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| UL1TR001079 | Institute for Clinical and Translational Research | FORD, DANIEL ERNEST | JOHNS HOPKINS UNIVERSITY | NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES | 2013 to 2017 |
Source NIH RePORTER
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Intervention vs Control: deaths from any cause | Trial comparisons |
| Intervention vs Control: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02523690
GET https://conductscience.org/api/trials/v1/NCT02523690/registered